Abstract
The patient diagnosed as recurrent pancreatic cancer was treated with UFT combined gemcitabine (GEM) chemotherapy. After one cycle of therapy, the anti-tumor effect was progressive disease with obstructive jaundice and enlargement of lymph node metastasis and liver metastasis. The chemotherapy was changed to TS-1 combined GEM chemotherapy and resulted in partial response. Only grade 3 leukopenia was observed as an adverse effect. Some cases may be effectively treated by TS-1 combined chemotherapy after treatment failure of UFT combined GEM chemotherapy. This therapy is simple and possible to continue safely on an ambulatory basis while maintaining quality of life.
Publication types
-
Case Reports
-
English Abstract
MeSH terms
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Deoxycytidine / administration & dosage
-
Deoxycytidine / analogs & derivatives
-
Drug Administration Schedule
-
Drug Combinations
-
Female
-
Gemcitabine
-
Humans
-
Jaundice, Obstructive / etiology
-
Liver Neoplasms / secondary
-
Lymph Nodes / pathology*
-
Lymphatic Metastasis
-
Middle Aged
-
Neoplasm Recurrence, Local / drug therapy*
-
Oxonic Acid / administration & dosage
-
Pancreatic Neoplasms / drug therapy*
-
Pancreatic Neoplasms / pathology
-
Pancreatic Neoplasms / surgery
-
Pyridines / administration & dosage
-
Quality of Life
-
Remission Induction
-
Tegafur / administration & dosage
-
Uracil / administration & dosage
Substances
-
Drug Combinations
-
Pyridines
-
UFT(R) drug
-
Deoxycytidine
-
S 1 (combination)
-
Tegafur
-
Uracil
-
Oxonic Acid
-
Gemcitabine